Products

BrainScope TBI
BrainScope
Clinical Decision Support & Reference
BrainScope TBI is an FDA-cleared, AI-powered EEG device for rapid, objective assessment of mild traumatic brain injury (mTBI), including concussions and brain bleeds, designed to reduce unnecessary head CTs at the point of care.
BrainScope Ahead 100
BrainScope
Neurology AI
BrainScope Ahead 100 is an FDA-cleared, AI-powered EEG device for rapid, non-invasive assessment of mild traumatic brain injury (mTBI), including concussions and brain bleeds, designed to reduce unnecessary CT scans.

See all 2 products →

About BrainScope

BrainScope is a medical neurotechnology company that specializes in AI-powered EEG-based diagnostic solutions for brain health. The company has developed a proprietary platform that utilizes machine learning and computational neuroscience to transform brain electrical activity (EEG) into objective clinical biomarkers. BrainScope’s flagship product, the BrainScope One system, is a portable, FDA-cleared device designed for point-of-care assessment of mild traumatic brain injuries (mTBI), including structural brain bleeds and concussions. This technology aims to provide rapid, radiation-free, and cost-effective insights, potentially reducing unnecessary head CT scans by approximately 50% and significantly decreasing patient length of stay in emergency departments.

Beyond acute head injury assessment, BrainScope is actively developing novel biomarkers for a broader spectrum of neurological conditions. These include early Alzheimer’s disease detection, with the potential to predict dementia risk years before a clinical diagnosis, as well as rapid stroke evaluation, ARIA (Amyloid-Related Imaging Abnormalities) assessment, concussion subtyping, and the evaluation of military blast exposure and brain fog. The company’s technology is built upon extensive research, including 28 clinical studies, 32 peer-reviewed journal articles, and eight FDA clearances, and is protected by a portfolio of 83 issued patents.

Focus Areas

mild traumatic brain injury concussion structural brain injury brain bleeds stroke neurodegenerative diseases Alzheimer's detection behavioral health neuroinflammatory disorders EEG-based biomarkers AI diagnostics

Business Intelligence

TechnologyAI-driven platform, machine learning, deep learning, computational neuroscience, electroencephalographic (EEG) data analysis, Large Neural Model platform, cloud-native (implied by data processing capabilities)

What Physicians Need to Know

Mild Traumatic Brain Injury (mTBI) & Concussion
BrainScope offers the only FDA-cleared, comprehensive, rapid, and radiation-free assessment for both brain bleeds and concussions. Their device can objectively assess head-injured patients for structural and functional mTBI in under 20 minutes, potentially reducing unnecessary head CTs by 31-60%.
Structural Brain Injury & Brain Bleeds
The BrainScope Structural Injury Classifier (SIC) indicates the likelihood of a CT-negative or CT-positive result with 99% sensitivity to detectable blood (≥1 mL) and a 98% negative predictive value.
Stroke Assessment
BrainScope's brain bleed biomarker has shown potential for higher sensitivity than CT machines in identifying ischemic stroke and high accuracy in distinguishing stroke from 'stroke mimics' in retrospective studies.
Neurodegenerative Diseases & Alzheimer's Detection
BrainScope is developing EEG-based biomarkers for early detection of Alzheimer's disease, with proof-of-concept studies showing the ability to predict cognitive decline years before diagnosis.
Behavioral Health & Neuroinflammatory Disorders
BrainScope is committed to creating transformative biomarkers for a range of CNS indications, including behavioral health and neuroinflammatory disorders.
EEG-based Biomarkers & AI Diagnostics
BrainScope's core technology leverages advanced digital signal processing of EEG data, AI, and machine learning algorithms to derive objective physiological biomarkers for brain injury and other neurological conditions.
Key Differentiators
BrainScope offers a portable, non-invasive, radiation-free, rapid (under 20 minutes), and cost-effective point-of-care solution. It's the first FDA-cleared AI/machine learning medical device in neurology for head injury assessment.
Technology Stack
The system includes a disposable electrode headset, a handheld display device (utilizing smartphone technology), and proprietary embedded software. It uses advanced digital signal processing, AI, machine learning, and deep learning algorithms to analyze EEG data. The device incorporates the international 10-20 electrode placement system.
Physician Tip

For physicians, BrainScope provides objective, rapid, and actionable insights at the point of care, aiding in confident clinical decision-making for head-injured patients. It can help rule out the need for head CTs, reduce patient length of stay in the ED, and provide objective measures for concussion diagnosis and management, including tracking recovery over time. The technology's ability to detect brain dysfunction early, even before structural damage, offers significant potential for timely intervention and improved patient outcomes across various neurological conditions.

BrainScope's system is designed for ease of integration into clinical workflows, with a handheld device for data acquisition and immediate results. The company also offers a cloud-based EEG-to-biomarker analytics platform that can ingest EEG and neurocognitive test data from proprietary or third-party devices.

Products by BrainScope

2 products in the directory

BrainScope TBI
BrainScope
Clinical Decision Support & Reference
BrainScope TBI is an FDA-cleared, AI-powered EEG device for rapid, objective assessment of mild traumatic brain injury (mTBI), including concussions and brain bleeds, designed to reduce unnecessary head CTs at the point of care.
BrainScope Ahead 100
BrainScope
Neurology AI
BrainScope Ahead 100 is an FDA-cleared, AI-powered EEG device for rapid, non-invasive assessment of mild traumatic brain injury (mTBI), including concussions and brain bleeds, designed to reduce unnecessary CT scans.

What the Web Says

BrainScope is generally viewed as an innovative company in the medical device space, particularly for its concussion assessment technology. Product reviews highlight its potential to objectively aid in diagnosing mild traumatic brain injury (mTBI), while employer reviews suggest a positive work environment with a focus on mission, though some challenges with growth and compensation are noted.

Overall: Mixed

Strengths

  • Innovative technology for objective concussion assessment (BrainScope One)
  • Addresses an unmet need in mTBI diagnosis
  • Positive company culture and mission-driven employees
  • Supportive management and good work-life balance (employer reviews)
  • Potential to improve patient care and reduce unnecessary CT scans
  • FDA-cleared device

Limitations

  • High cost of the device can be a barrier to adoption for some facilities
  • Limited widespread adoption and market penetration so far
  • Some employer reviews mention challenges with compensation/salary compared to larger companies
  • Growth opportunities can be limited in certain roles (employer reviews)
  • Learning curve for new users of the device
  • Reliance on specific clinical pathways for optimal use

Based on reviews from: G2, Glassdoor, Capterra, Healthcare IT News, Reddit, FierceBiotech, MedTech Dive

Last updated: 2026-10-18

Videos

News, demos, and interviews about BrainScope.

Loading videos...

Videos load interactively. If none appear, search YouTube for BrainScope →

View all on YouTube

Press & Coverage

BrainScope
BrainScope CEO Matt Adams Appears on BioTalk Podcast
BrainScope CEO Matt Adams discussed the future of objective brain health measurement and how BrainScope combines EEG technology with artificial intelligence on the BioTalk podcast.
2026-08
Business Wire
BrainScope's EEG-Based Biomarker Predicts Dementia Risk Up to 7 Years Before Initial Diagnosis, Published in Nature Scientific Reports
A longitudinal study published in Nature Scientific Reports shows BrainScope's non-invasive, point-of-care EEG technology can detect functional changes in brain activity, predicting dementia risk up to seven years before diagnosis.
2026-02
BrainScope
BrainScope Strengthens Executive Team with Veteran Commercial Leader David Wingate
BrainScope appointed David Wingate as VP of Sales, bringing over 30 years of medtech leadership experience to accelerate the adoption of AI-enabled brain health solutions.
2026-05
BrainScope
BrainScope Names Matt Adams as Chief Executive Officer
Matt Adams, with over 20 years of medtech experience, was appointed as the new Chief Executive Officer of BrainScope, succeeding Laurie Silver.
2025-11
Business Wire
BrainScope Expands Board and Launches Advanced Deep Learning Platform to Enhance Brain Health Insights
BrainScope launched its next-generation deep learning platform, enhancing its AI-enabled EEG technology to deliver faster, objective insights across brain health conditions like concussion, stroke, and early Alzheimer's detection.
2025-06
BrainScope
BrainScope Completes Proof-of-Concept for Groundbreaking Early Alzheimer's Prediction Biomarker
BrainScope successfully completed the proof-of-concept phase for a novel brain activity-based biomarker to predict the onset of Alzheimer's disease at its earliest stage, supported by an investment from the Alzheimer's Drug Discovery Foundation.
2024-10
BrainScope
BrainScope Receives Investment from the Alzheimer's Drug Discovery Foundation for Alzheimer's Prediction Biomarker
The Alzheimer's Drug Discovery Foundation (ADDF) invested in BrainScope's Series B equity financing round to support the development of an AI/Machine Learning-derived biomarker for predicting Alzheimer's onset.
2023-09
PRNewswire (via BrainScope)
Tri-anim Health Services Announces Exclusive Relationship to Distribute BrainScope's Breakthrough Technology for Mild Head Injury Including Concussion
Tri-anim Health Services entered an exclusive agreement to distribute BrainScope's device in hospital Emergency Departments, providing an innovative point-of-care tool for objectively assessing mild head injuries and concussions.
2022-09

Frequently Asked Questions

BrainScope's technology is primarily designed to objectively assess patients with suspected mild traumatic brain injury (mTBI), including concussion. It helps clinicians determine the likelihood of both structural brain injury (such as brain bleeds) that may require a CT scan and functional brain injury, aiding in the overall evaluation and management of these patients.
BrainScope utilizes EEG-based biomarkers combined with proprietary algorithms and AI to analyze brain electrical activity. This approach helps differentiate between the presence or absence of structural brain injury visible on CT and functional impairments associated with concussion, providing objective data to support clinical decision-making.
BrainScope's flagship product, the BrainScope One, is a portable, non-invasive medical device that provides objective insights into brain injury. It is designed for use at the point of care, integrating into emergency departments, urgent care centers, and athletic training facilities to streamline the assessment of head-injured patients.
BrainScope's technology has undergone extensive clinical validation, with numerous studies demonstrating its accuracy in identifying structural and functional brain injuries. It is FDA-cleared, meeting stringent regulatory compliance standards for medical devices, ensuring its safety and effectiveness for clinical use.
BrainScope offers various pricing models, which can include per-use fees or device purchase options, tailored to the needs of different healthcare settings. The company provides comprehensive training and ongoing support to ensure healthcare providers can effectively integrate and utilize the technology in their practice.
While BrainScope's primary focus is on acute mild traumatic brain injury, the underlying EEG-based biomarker technology holds potential for future applications in other neurological and behavioral health areas. However, current FDA clearances and product offerings are specifically for mTBI assessment.
BrainScope has established partnerships with various healthcare organizations and research institutions to further advance its technology and expand its reach. The company is committed to ongoing innovation and aims to become a standard of care for objective brain injury assessment, demonstrating a strong vision for long-term stability and growth.

Related Companies

A2z Radiology AI is a Boston-based medical imaging AI company that develops software for comprehensive CT interpretation, initially focusing on abdomen-pelvis CT scans. The company’s primary goal is to enhance diagnostic accuracy and efficiency in medical imaging for healthcare providers by leveraging artificial intelligence. Their flagship product, a2z-Unified-Triage, is FDA-cleared radiological computer-aided triage and notification […]

OpenAI is an American artificial intelligence (AI) company that conducts research and develops advanced AI models. While widely known for its generative AI models like ChatGPT and DALL-E, OpenAI has significantly expanded its focus into the healthcare sector. The company’s mission is to ensure that artificial general intelligence (AGI) benefits all of humanity, and this […]

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]

Veeva Systems is a global leader in cloud-based software solutions specifically designed for the life sciences industry, including pharmaceutical and biotech companies. The company’s offerings are crucial for managing various aspects of drug development, pharmaceutical manufacturing, and commercial operations. Their platforms help clients navigate complex regulatory requirements, improve operational efficiency, and accelerate the delivery of […]

The University at Buffalo (UB) is a prominent public research university and a flagship institution of the State University of New York (SUNY) system. While UB itself is a broad academic institution, the provided URL (halsted.compbio.buffalo.edu) points to a specific area within UB focused on computational biology. This division is actively engaged in healthcare AI […]

Prenaital is an AI-driven healthcare company focused on revolutionizing maternal care by improving the early detection and management of high-risk pregnancies. Their AI models analyze ultrasound images to identify at-risk pregnancies, including those with abnormal fetal growth and a risk of preterm birth, with significantly higher accuracy than current clinical practices—detecting 25-50% more high-risk cases. […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.